Navigation Links
Helix BioPharma to Present at the BioFinance 2009 Conference
Date:4/24/2009

AURORA, Ontario, April 24 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced that John Docherty, president and chief operating officer, will present at the BioFinance 2009 Investor Conference at 3:00 p.m. EDT on Wednesday, April 29, at The Toronto Marriott in Toronto. Mr. Docherty will provide an overview of the company's leading technology platforms, DOS47 and Biphasix(TM), and its current product development programs, L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on April 29, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

    For further information contact:

    Investor & Media Relations
    Ian Stone                           Robert Flamm, Ph.D.
    Russo Partners LLC                  Russo Partners LLC
    Tel: (619) 814-3510                 Tel: (212) 845-4226
    Fax: (619) 955-5318                 Email:
    Email:                               robert.flamm@russopartnersllc.com
     ian.stone@russopartnersllc.com     www.russopartnersllc.com

This News Release contains certain forward-looking statements regarding the Company's planned presentation at the BioFinance 2009 Investor Conference and the Company's research and development initiatives, which statements can be identified
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Edison ... firm, announces the initiation of full coverage ... company developing and marketing products for orphan ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison ... the investment merits of BioAlliance Pharma, focusing ...
(Date:6/18/2013)...  Techne Corporation (NASDAQ: TECH ) ... acquire 100% ownership of Bionostics Holdings Limited and ... a global leader in the development, manufacture and ... operation of in vitro diagnostic (IVD) ... glucose and blood gas testing.  Biosnostics has strategic ...
(Date:6/18/2013)... Texas , June 18, 2013   ... ), a biopharmaceutical company focused on discovering breakthrough ... John Northcott has joined the company as ... operations. Mr. Northcott brings extensive commercial experience to ... across a variety of therapeutic areas. ...
(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... therapy with Pfizer,s recently ... MALIBU, Calif., Nov. 15 Pathway Diagnostics announces,that ... U.S. Patent,number 7,294,458 (the ,458 patent) entitled "Analysis of ... Pathway Diagnostics,has licensed the ,458 patent (with rights to ...
... WYE ),today announced that its Board of Directors ... effective immediately. Mr. Davidson will,continue in his role as ... and divisional financial positions since joining the Company,in 1984. ... Chief,Financial Officer, Wyeth Consumer Healthcare and Deputy Treasurer, Wyeth. ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that ... September 30, 2007. Net,revenues totaled $7,373,770 for the quarter ... in 2006. Gross profit decreased by 2.66% due to ... from Aida,s,transfusion and injection forms of etimicin sulfate increased ...
Cached Biology Technology:Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy 2Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4
(Date:6/18/2013)... Obar, Ph.D., Department of Immunology and Infectious Diseases, Montana ... Young Investigator Award for his research on factors affecting ... , Obar earned his B.A. in Microbiology from ... complete his Ph.D. in Microbiology and Immunology from Dartmouth ... research in Edward Usherwood,s laboratory at the Geisel School ...
(Date:6/18/2013)... A team of internationally recognized feline experts including veterinarians ... the University of Lincoln, U.K. and Dr Ilona Rodan, ... by the International Society of Feline Medicine (ISFM) and ... guidelines for veterinarians, owners and those working with cats ... domestic cat. The new guidelines appear in the ...
(Date:6/17/2013)... LA JOLLA, CA June 17, 2013 An ... Institute (TSRI), the Howard Hughes Medical Institute and Albert ... a highly promising new anti-tuberculosis compound that attacks the ... findings represent an effort to help solve one of ... of TB and its dangerous drug-resistant strains," said Peter ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Joshua Obar 2Feline behavior experts release guidelines to improve the welfare of cats 2New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4
... more serious threat to marine life than previously thought. ... (19 July) in the British Ecological Society,s Journal ... of turtles from across the Pacific are being captured ... fisheries in Peru, the study suggests that thousands of ...
... Those solar panels on top of your roof aren,t ... your workplace, too, according to a team of researchers led ... UC San Diego Jacobs School of Engineering. , In ... Solar Energy , Kleissl and his team published what they ...
... 2011) Researchers from the John Theurer Cancer Center ... cancer-related studies during the recently concluded American Society of ... 3 7, 2011 in Chicago. The studies examined ... outcomes, and patient quality of life issues. ...
Cached Biology News:Study shows small-scale fisheries' impact on marine life 2Solar Panels Keep Buildings Cool 2Solar Panels Keep Buildings Cool 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6
... Immunogen KLH-conjugated, synthetic ... 47-66 (PAEV-GPGAVGERTPRKKEPP) of human BRAF-HDAC ... (BHC110/LSD1). Quality Assurance ... Stability 2 years ...
Request Info...
...
...
Biology Products: